Search
Now showing items 31-40 of 83
Carcinoma of unknown primary: Natural history and treatment. Analysis of 30 cases and review of the literature
(1990)
In this study, the natural history and therapeutic management of 30 patients with carcinoma of unknown primary (CUP syndrome) is presented. Despite detailed laboratory investigations, the primary occult tumor was not ...
Evaluation of six tumor markers in patients with carcinoma of unknown primary
(1994)
We have retrospectively evaluated six serum tumor markers in 85 patients with carcinoma of unknown primary. The serum levels of carcinoembryonic antigen (CEA), CA 19‐9, CA 15‐3, CA 125, β‐chorionic gonadotropin (β‐HCG) and ...
Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: A phase II study
(1997)
Background: Based on the high activity of single-agent paclitaxel and the superior one-year survival rates of patients with non-small-cell lung cancer (NSCLC) treated with carboplatin, a phase II trial was initiated using ...
Serum‐soluble interleukin‐2 receptors in B‐cell lymphoproliferative malignancies
(1992)
The levels of soluble interleukin‐2 receptors (sIL‐2R) were determined in the serum of 53 patients with B‐cell lymphoproliferative malignancies, including 31 patients with non‐Hodgkin lymphomas (NHL), 16 with chronic ...
A successfully treated case of multicentric angiofollicular hyperplasia with oral chemotherapy (Castleman's disease)
(1990)
A case of angiofollicular lymph node hyperplasia of plasma cell type in a 60‐year‐old woman is reported. The patient presented with lymphadenopathy, splenomegaly, and fever. She responded dramatically to chlorambucil and ...
Weekly alternating non-cross-resistant chemotherapy for small cell lung cancer with a good prognosis: A study of the Hellenic Cooperative Oncology Group
(1999)
This trial was conducted by the Hellenic Cooperative Oncology Group to improve the responses and survival in small cell lung cancer with a good prognosis, using a weekly intensive chemotherapy with alternated non-cross- ...
p53/MDM-2 immunohistochemical expression correlated with proliferative activity in different subtypes of human sarcomas: A ten-year follow-up study
(1998)
The aim of this study was the evaluation of p53/MDM-2 protein overexpression in different subtypes of human sarcomas, and their correlation with proliferative activity and patient outcome. We selected 40 cases of human ...
Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: Biological and clinical implications. A Hellenic co-operative oncology group study
(1998)
We have previously shown that metastatic carcinomas of unknown primary site overexpress several tumor markers as well as the products of the oncogenes c-myc, ras and c-erbB2. We analysed the tissue expression of the protein ...
Primary extranodal non-hodgkin's lymphoma of the head and neck
(1992)
Among 387 cases of non-Hodgkin's lymphoma (NHL) treated in our units between January 1977 and December 1990, 52 (13.4%) had primary extranodal (PE) NHL of the head and neck. The median age was 55 years with a M:F ratio of ...
Overexpression of C-myc, ras and C-erb B-2 oncoproteins in carcinoma of unknown primary origin
(1995)
The role of oncogenes in carcinoma of unknown primary site (CUP) has not yet been elucidated. In the present study the expression of the c-myc p62, ras p21 and c-erb B p185 oncoproteins were studied by a 3-step immunoperoxidase ...